(Q36916853)

17 August 2017

1 reference

title

Discontinued drugs in 2006: pulmonary-allergy, dermatological, gastrointestinal and arthritis drugs (English)

1 reference

17 August 2017

2

Cezmi A Akdis

1 reference

17 August 2017

Cevdet Ozdemir

1

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

Expert Opinion on Investigational Drugs

17 August 2017

published in

1 reference

17 August 2017

volume

16

1 reference

17 August 2017

issue

9

1 reference

17 August 2017

page(s)

1327-1344

1 reference

Evaluation of the effect of multiple-dose administration of R411, a dual alpha4beta1-alpha4beta7 integrin antagonist on the major CYP isoform activities in healthy volunteers

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1327

Rational design of potent and selective VLA-4 inhibitors and their utility in the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1327

Prostanoids as pharmacological targets in COPD and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1327

Surfactant therapy in adults with acute lung injury/acute respiratory distress syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1327

Effect of anti-IgE therapy in patients with peanut allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1327

Clinical trials of transplant tolerance: slow but steady progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1327

Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1327

RDP58 is a novel and potentially effective oral therapy for ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1327

Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1327

Kinetics and dynamics of the peripheral neurokinin-1 receptor antagonist SLV317 in healthy individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1327

Review article: new pharmacological agents for the treatment of gastro-oesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1327

Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1327

Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1327

Emerging roles of cysteine cathepsins in disease and their potential as drug targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1327

FK778: New Cellular and Molecular Mechanisms of Action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.9.1327

10.1517/13543784.16.9.1327

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference